A CASE OF ACRAL LENTIGINOUS MELANOMA WITH EVALUATION OF С-KIT GENE EXON 11 MUTATION STATUS
- Authors: Komina A.V1, Aksenenko M.B1, Sergeeva O.N1, Kirichenko A.K1, Ruksha T.G.1
-
Affiliations:
- Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky
- Issue: Vol 20, No 5 (2017)
- Pages: 267-269
- Section: Articles
- URL: https://journals.rcsi.science/1560-9588/article/view/42717
- DOI: https://doi.org/10.18821/1560-9588-2017-20-5-267-269
- ID: 42717
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A. V Komina
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-YasenetskyKrasnoyarsk, 660022, Russian Federation
M. B Aksenenko
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-YasenetskyKrasnoyarsk, 660022, Russian Federation
O. N Sergeeva
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-YasenetskyKrasnoyarsk, 660022, Russian Federation
A. K Kirichenko
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-YasenetskyKrasnoyarsk, 660022, Russian Federation
Tatiana G. Ruksha
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky
Email: tatyana_ruksha@mail.ru
MD, PhD, DSc., head of Department of pathophysiology of KrasSMU n.a. prof. V.F. Voyno-Yasenetsky, Krasnoyarsk, 660022, Russian Federation Krasnoyarsk, 660022, Russian Federation
References
- Reed R. Acral lentiginous melanoma. In: Hartmann W., Reed R., eds. New concepts in surgical pathology of the skin. New York: Wiley; 1976: 89-90.
- Markovic S.N., Erickson L.A., Rao R.D., Weenig R.H., Pockaj B.A., Bardia A., et al.; Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin. Proc. 2007; 82(3): 364-80.
- Lee H.Y., Chay W.Y., Tang M.B., Chio M.T., Tan S.H. Melanoma: differences between Asian and Caucasian patients. Ann. Acad. Med. Singapore. 2012; 41(1): 17-20.
- Lee M.W., Koh J.K., Kwon K.S., Kim N.I., Kim S.W., Kim S.N., et al. Clinical and histopathological study of cutaneous melanoma in Korea. Korean J. Dermatol. 2003; 41: 43-47.
- Phan A., Touzet S., Dalle S., Ronger-Savle S., Balme B., Thomas L. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br. J. Dermatol. 2006; 155(3): 561-9.
- Feibleman C.E., Stoll H., Maize J.C. Melanomas of the palm, sole, and nail bed: a clinicopathologic study. Cancer. 1980; 46(11): 2492-504.
- Stalkup J.R., Orengo I.F., Katta R. Controversies in acral lentiginous melanoma. Dermatol. Surg. 2002; 28(11): 1051-9.
- Breslow A. Prognostic factors in the treatment of cutaneous melanoma. J. Cutan. Pathol. 1979; 6(3): 208-12.
- Bristow I.R., Acland K. Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature. J. Foot Ankle Res. 2008; 1(1): 11. doi: 10.1186/1757-1146-1-11.
- Phan A., Dalle S., Touzet S., Ronger-Savlé S., Balme B., Thomas L. Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population. Br. J. Dermatol. 2010; 162(4): 765-771.
- Nakamura Y., Teramoto Y., Sato S., Yamamoto A. Ch. 5. Current surgical management of acral lentiginous melanoma. In: Murph M., ed. Melanoma - Current Clinical Management and Future Therapeutics. InTech, Chapters published; 2015. doi: 10.5772/59133. Available at: https://www.intechopen.com/books/melanoma-current-clinical-management-and-future-therapeutics/current-surgical-management-of-acral-lentiginous-melanoma (accessed 23 June 2017)
- Ashida A., Takata M., Murata H., Kido K., Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int. J. Cancer. 2009; 124(4): 862-8.
- Beadling C., Jacobson-Dunlop E., Hodi F.S., Le C., Warrick A., Patterson J., et al. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 2008; 14(21): 6821-8.
- Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006; 24(26): 4340-6.
- Carvajal R.D. Targeting KIT for treatment of advanced melanoma. Melanoma Lett. 2011; 29(3): 1-4.
- Hodi F.S., Corless C.L., Giobbie-Hurder A., Fletcher J.A., Zhu M., Marino-Enriquez A., et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol. 2013; 31(26): 3182-90.
- Garrido M., Bastian B.C. KIT as a therapeutic target in melanoma. J. Invest. Dermatol. 2010; 130(1): 20-7.
- Forbes S.A., Beare D., Boutselakis H., Bamford S, Bindal N., Tate J., et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017; 45(D1): D777-83. doi: 10.1093/nar/gkw1121.